Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.

Primary tabs

field_vote: 
Average: 7 (1 vote)
Publication type: 
Number of included patients: 
References: 
Therapeutic intervention: 
Disease(s): 
Therapeutic Substance(s): 

Cancer Biol Ther. 2008 Jun;7(6):810-3.

Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
 
Gudena V, Verma N, Post G, Kizziah M, Fenning R, Montero AJ.
 
Department of Hematology-Oncology, Medical University of South Carolina, Charleston, South Carolina 29425, USA.
Malignant
schwannomas or malignant peripheral nerve sheath tumors (MPNST)
represent approximately 10% of all soft tissue sarcomas. Metastatic
disease from chest wall MPNST is very rare. We present a case of a
major clinical response to the tyrosine kinase inhibitor (TKI)
sorafenib in a patient with metastatic MPNST. A 42-year-old female with
a prior history of neurofibromas developed MPNST, which later
metastasized to the lungs and brain. She was initially placed on
sorafenib with significant clinical response to lung metastases. MPNST
show high levels of Ras activity and hence these tumors are promising
targets for TKIs. Studies are ongoing and the results are eagerly
awaited regarding the responses to these medications and whether they
can positively impact on the natural history of this disease.